Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This patent, which is one of many held by Qiagen protecting the QuantiFERON technology, covers important innovations in QuantiFERON-TB Gold Plus that is used worldwide for TB detection.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen price target lowered to EUR 48 from EUR 54.90 at Berenberg
- Electronic Arts initiated, Workday downgraded: Wall Street’s top analyst calls
- Optimistic Buy Rating for Qiagen: Market Position and Strategic Advancements Drive Growth Prospects
- Qiagen downgraded to Neutral from Outperform at Baird
- Qiagen Exceeds 2024 Financial Outlook with Solid Growth
Questions or Comments about the article? Write to editor@tipranks.com